Business Wire

NY-UPTIME-INSTITUTE

8.6.2022 12:04:10 CEST | Business Wire | Press release

Share
Uptime Institute’s 2022 Outage Analysis Finds Downtime Costs and Consequences Worsening as Industry Efforts to Curb Outage Frequency Fall Short

The digital infrastructure sector is struggling to achieve a measurable reduction in outage rates and severity, and the financial consequences and overall disruption from outages are steadily increasing, according to Uptime Institute , which today released the findings of its 2022 annual Outage Analysis report.

“Digital infrastructure operators are still struggling to meet the high standards that customers expect and service level agreements demand – despite improving technologies and the industry’s strong investment in resiliency and downtime prevention,” said Andy Lawrence, founding member and executive director, Uptime Institute Intelligence .

“The lack of improvement in overall outage rates is partly the result of the immensity of recent investment in digital infrastructure, and all the associated complexity that operators face as they transition to hybrid, distributed architectures,” said Lawrence. “In time, both the technology and operational practices will improve, but at present, outages remain a top concern for customers, investors, and regulators. Operators will be best able to meet the challenge with rigorous staff training and operational procedures to mitigate the human error behind many of these failures.”

Uptime’s annual outage analysis is unique in the industry, and draws on multiple surveys, information supplied by Uptime Institute members and partners, and its database of publicly reported outages.

Key Findings Include :

  • High outage rates haven’t changed significantly. One in five organizations report experiencing a “serious” or “severe” outage (involving significant financial losses, reputational damage, compliance breaches and in some severe cases, loss of life) in the past three years, marking a slight upward trend in the prevalence of major outages. According to Uptime’s 2022 Data Center Resiliency Survey, 80% of data center managers and operators have experienced some type of outage in the past three years – a marginal increase over the norm, which has fluctuated between 70% and 80%.
  • The proportion of outages costing over $100,000 has soared in recent years. Over 60% of failures result in at least $100,000 in total losses, up substantially from 39% in 2019. The share of outages that cost upwards of $1 million increased from 11% to 15% over that same period.
  • Power-related problems continue to dog data center operators. Power-related outages account for 43% of outages that are classified as significant (causing downtime and financial loss). The single biggest cause of power incidents is uninterruptible power supply (UPS) failures.
  • Networking issues are causing a large portion of IT outages. According to Uptime’s 2022 Data Center Resiliency Survey, networking-related problems have been the single biggest cause of all IT service downtime incidents – regardless of severity – over the past three years. Outages attributed to software, network and systems issues are on the rise due to complexities from the increasing use of cloud technologies, software-defined architectures and hybrid, distributed architectures.
  • The overwhelming majority of human error-related outages involve ignored or inadequate procedures. Nearly 40% of organizations have suffered a major outage caused by human error over the past three years. Of these incidents, 85% stem from staff failing to follow procedures or from flaws in the processes and procedures themselves.
  • External IT providers cause most major public outages. The more workloads that are outsourced to external providers, the more these operators account for high-profile, public outages. Third-party, commercial IT operators (including cloud, hosting, colocation, telecommunication providers, etc.) account for 63% of all publicly reported outages that Uptime has tracked since 2016. In 2021, commercial operators caused 70% of all outages.
  • Prolonged downtime is becoming more common in publicly reported outages. The gap between the beginning of a major public outage and full recovery has stretched significantly over the last five years. Nearly 30% of these outages in 2021 lasted more than 24 hours, a disturbing increase from just 8% in 2017.
  • Public outage trends suggest there will be at least 20 serious, high-profile IT outages worldwide each year. Of the 108 publicly reported outages in 2021, 27 were serious or severe. This ratio has been fairly consistent since the Uptime Intelligence team began cataloging major outages in 2016, indicating that roughly one-fourth of publicly recorded outages each year are likely to be serious or severe.

Learn More : For further insight into Uptime’s latest research on digital infrastructure failures, register to attend the upcoming 2022 Outage Report webinar on Thursday, June 16th at 9:00 a.m. PDT here .

The complete report is available exclusively for the Uptime Institute Membership Network, the world’s largest group of data center owners and operators. Learn more about Uptime Institute Membership and request a free guest trial here .

About Uptime Institute

Uptime Institute is the Global Digital Infrastructure Authority. Its Tier Standard is the IT industry’s most trusted and adopted global standard for the proper design, construction, and operation of data centers – the backbone of the digital economy. For over 25 years, the company has served as the standard for data center reliability, sustainability, and efficiency, providing customers assurance that their digital infrastructure can perform at a level that is consistent with their business needs across a wide array of operating conditions. With its data center Tier Standard & Certifications, Management & Operations reviews, broad range of related risk and performance assessments, and accredited educational curriculum completed by over 10,000 data center professionals, Uptime Institute has helped thousands of companies, in over 100 countries to optimize critical IT assets while managing costs, resources, and efficiency.

Uptime Institute is headquartered in New York, NY, with offices in Seattle, London, Sao Paulo, Dubai, Singapore, and Taipei and staff in over 25 other countries. For more information, please visit www.uptimeinstitute.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye